Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Disease Area Drug discovery, Infectious diseases

Targeting Tuberculosis

Although entering a new era of innovative and personalized medicine in industrialized countries, we still rely on drugs developed more than 50 years ago to treat neglected diseases such as tuberculosis (TB). Since then, only two new drugs, Sirturo (bedaquiline) and Deltyba (delamanid), have been approved for treating TB. Because they are not known to be more effective than traditional frontline TB antibiotics, they are only used to treat multidrug or extensively drug resistant cases, which sometimes are incurable. In recent years, governments and pharmaceutical companies are recognizing an urgent need to improve current TB treatments. In addition to the well-recognized challenges of drug development, TB antibiotic development is particularly limited for a number of reasons, including:

  • The causative agent of TB, Mycobacterium tuberculosis, is intrinsically resistant to most available antibiotics.

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!


Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Santiago Ramón-García

Santiago Ramón-García is Principal Investigator at the Research Agency of Aragon (ARAID), Zaragoza, Spain, and Charles Thompson, Principal Investigator at the Thompson Lab at the University of British Columbia, Canada.


Send me the latest from The Translational Scientist.

Sign up now

Related Articles

Research Field Cancer

Cancer and the Microbiome

| Ivan Gladwyn-Ng, Alexander Maue

Research Field Neurological

Redirecting Cell Fate

| Jonathan James

Disease Area Cancer

Two-pronged Attack on Neuroblastoma

| Jonathan James

Most Popular

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts